Tag: Interferon (IFN)

Emerging intralesional therapies for BCC

Presented By
Dr Antonio Cozzio, Kantonsspital St Gallen, Switzerland
Conference
DDD 2025
Type
Peer-reviewed article

5 June 2025 11:30

Emapalumab rapidly controls MAS in patients with Still’s disease

Presented By
Dr Alexei Grom, Cincinnati Children's Hospital, OH, USA
Trial
NI-0501-06, EMERALD
Conference
ACR 2024
Type
Peer-reviewed article

13 January 2025 11:17

New insights into perianal fistulising CD pathogenesis may lead to new therapies

Presented By
Dr Siyan Cao, Washington University, USA
Conference
UEGW 2024
Type
Peer-reviewed article

28 November 2024 11:23

DALIAH: Peginterferon-α head-to-head against hydroxyurea in MPN

Presented By
Dr Trine Knudsen, University Hospital Odense, Denmark
Trial
Phase 3, DALIAH
Conference
ASH 2023
Type
Peer-reviewed article

7 February 2024 14:57

Ocrelizumab more effective than interferon/glatiramer acetate in older MS patients

Presented By
Dr Yi Chao Foong, Monash University, Australia
Conference
MSMilan 2023
Type
Peer-reviewed article

4 December 2023 11:09

Real-world data supports ocrelizumab prior to conception

Presented By
Dr Wei Yeh, Alfred Health and Monash University, Australia
Conference
MSMilan 2023
Type
Peer-reviewed article

4 December 2023 11:07

Inhaled agent under investigation for COVID-19 

Presented By
Prof. Tom Wilkinson, University of Southampton, UK
Trial
Phase 3, SPRINTER
Conference
ERS 2022
Type
Peer-reviewed article

30 October 2022 20:22

SPRINTER: SNG001 still in the running?

Presented By
Dr Philip Monk , Synairgen Research LtD, UK
Trial
Phase 3, SPRINTER
Conference
ATS 2022
Type
Peer-reviewed article

18 July 2022 14:04

JAK inhibition offers promising treatment prospects for uncommon dermatoses

Presented By
Prof. Matthew Vesely, Yale School of Medicine, USA
Conference
AAD 2022
Type
Peer-reviewed article

17 May 2022 11:48

JAK inhibitors may offer a new horizon in the treatment of sarcoidosis

Presented By
Prof. William Damsky, Yale School of Medicine, USA
Conference
AAD 2022
Type
Peer-reviewed article

17 May 2022 11:12

The Yin and Yang of opposing vectors: an explanation for side effects of biologics

Presented By
Prof. Curdin Conrad, Lausanne University Hospital, Switzerland
Conference
PFGC 2021
Type
Peer-reviewed article

3 February 2022 11:07

Explaining arthropathy development through IL-4 and IL-13 blockade

Presented By
Dr Charlie Bridgewood, University of Leeds, UK
Conference
PFGC 2021
Type
Peer-reviewed article

3 February 2022 10:51

Personality trait alterations in MS patients

Presented By
Dr Laura Chu, Memorial University of Newfoundland, Canada
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 15:49

ECTRIMS/EAN Clinical Guidelines on MS treatment: an update

Presented By
Prof. Xavier Montalban, Vall d’Hebron University Hospital, Spain
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 14:37

Rituximab most effective initial MS therapy in Swedish real-world study

Presented By
Mr Peter Alping, Karolinska Institutet, Sweden
Trial
Phase 4, COMBAT-MS
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 14:36

Long-term suppression of MRI disease activity with ocrelizumab

Presented By
Dr Douglas Arnold, McGill University, Canada
Trial
Phase 3, OPERA I/II, ORATORIO
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 14:30

Primary endpoint of opicinumab for relapsing MS not met in AFFINITY trial

Presented By
Prof. Peter Calabresi, Johns Hopkins University, MD, USA
Trial
Phase 2, AFFINITY
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 14:12

ECTRIMS-EAN consensus on vaccination in MS patients

Presented By
Dr Mauricio Farez, Fundacion FLENI, Argentina
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 10:35

IFN-γ signature predicts response to immunotherapy

Presented By
Prof. Christian Blank, Netherlands Cancer Institute, the Netherlands
Trial
Phase 1, DONIMI
Conference
ESMO 2021
Type
Peer-reviewed article

19 November 2021 09:30

Novel and upcoming targeted AD treatment

Presented By
Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA
Trial
ECZTRA 3; Measure Up; ADVISE
Conference
EADV 2021
Type
Peer-reviewed article

18 November 2021 13:20

Serum NfL projects development of definite MS

Trial
Phase 3, REFLEX
Conference
AAN 2021
Type
Peer-reviewed article

16 June 2021 11:52

MS therapies influence COVID-19 severity

Conference
AAN 2021
Type
Peer-reviewed article

16 June 2021 11:42

No increased risk with IFN-β use during pregnancy

Conference
ECF 2020
Type
News article

16 December 2020 16:08

Risk of COVID-19 not increased in MS patients

Conference
MS Virtual 2020
Type
Peer-reviewed article

25 November 2020 17:10

Age and EDSS are risk factors for severe COVID-19

Trial
Cohort study, COVISEP
Conference
MS Virtual 2020
Type
Peer-reviewed article

25 November 2020 17:09

Management of progressive MS with approved DMT

Presented By
Prof. Xavier Montalban, Vall d'Hebron University Hospital, Spain
Trial
ASCEND, MS-SMART
Conference
MS Virtual 2020
Type
Peer-reviewed article

25 November 2020 17:01

Less thalamic atrophy in patients initiating ocrelizumab earlier

Conference
MS Virtual
Type
Peer-reviewed article

25 November 2020 16:59

Safety and efficacy of cladribine, glatiramer acetate, and more

Trial
CLASSIC-MS, OPTIMUM
Conference
MS Virtual 2020
Type
Peer-reviewed article

25 November 2020 16:55

Functional potential of gut microbiome in paediatric MS

Conference
MS Virtual 2020
Type
Peer-reviewed article

25 November 2020 16:49

Alemtuzumab efficacy and safety data of over 9 years

Presented By
Dr T. Ziemssen, Dr J. Jones, Prof. P. Vermersch
Trial
Phase 3, CARE-MS
Conference
EAN 2020
Type
Peer-reviewed article

10 September 2020 12:07

Nadofaragene firadenovec effective in BCG-unresponsive papillary NMIBC

Presented By
Dr Neal Shore, Carolina Urologic Research Center, USA
Conference
EAU 2020
Type
Peer-reviewed article

20 August 2020 12:44

Long-term data of ropeginterferon alpha-2b in polycythaemia vera

Presented By
Prof. Jean-Jacques Kiladjian, Saint Louis Hospital, France
Trial
PROUD-PV
Conference
ASH 2019
Type
Peer-reviewed article

5 March 2020 18:53

20-Year follow-up of imatinib in chronic myeloid leukaemia after failure with interferon

Presented By
Dr Maria Vazquez, MD Anderson Cancer Center, Houston, USA
Conference
ASH 2019
Type
Peer-reviewed article

5 March 2020 16:26

Anifrolumab succeeds in second phase 3 trial in SLE

Presented By
Prof. Eric Morand, Prof. Richard Furie
Trial
Phase 3, TULIP
Conference
ACR 2019
Type
Peer-reviewed article

4 February 2020 23:44

Topical ruxolitinib effective in vitiligo

Presented By
Prof. Amit Pandya, University of Texas Southwestern Medical Center, USA
Conference
EADV 2019

9 December 2019 13:08

Treatment escalation over induction therapy

Presented By
Dr Emmanuelle Waubant, University of California, San Francisco, USA
Conference
ECTRIMS 2019
Type
Peer-reviewed article

8 November 2019 22:40

Foetal/child perspective: risks related to drug exposure and breastfeeding

Presented By
Dr Kerstin Hellwig, Ruhr-Universität Bochum, Germany
Conference
ECTRIMS 2019
Type
Peer-reviewed article

8 November 2019 22:29

Serum immunoglobulin levels and risk of serious infections

Presented By
Prof. Tobias Derfuss, University Hospital Basel, Switzerland
Conference
ECTRIMS 2019
Type
Peer-reviewed article

8 November 2019 19:23

Inflammation may change the course of Parkinson’s disease

Presented By
Prof. Vidar Gundersen, University of Oslo, Norway
Conference
EAN 2019
Type
Peer-reviewed article

27 September 2019 23:47

Emapalumab in patients with macrophage activation syndrome

Presented By
Dr Fabrizio De Benedetti, Ospedale Pediatrico Bambino Gesù, Italy
Conference
EULAR 2019
Type
Peer-reviewed article

4 September 2019 20:51

Randomised and observational studies comparing treatments

Presented By
Prof. Giancarlo Comi, Vita-Salute San Raffaele University, Italy
Trial
Phase 3, SUNBEAM and RADIANCE
Conference
EAN 2019
Type
Peer-reviewed article

27 August 2019 20:34

Novel treatment options in alopecia areata and vitiligo

Presented By
Prof. Brett King, Yale University School of Medicine, USA
Conference
WCD 2019
Type
Peer-reviewed article

26 August 2019 18:20

New targets and biologics for cutaneous lupus erythematosus

Presented By
Prof. Victoria P. Werth, University of Pennsylvania, USA
Conference
WCD 2019
Type
Peer-reviewed article

26 August 2019 15:59

Molecular effects of ustekinumab

Trial
Phase 3, UNITI
Conference
ECCO 2019
Type
Peer-reviewed article

9 May 2019 19:47

JAK inhibitors: a pathogenesis-directed therapy for alopecia areata

Presented By
Prof. Brittany Craiglow, Yale University School of Medicine, USA
Conference
AAD 2019
Type
Peer-reviewed article

19 April 2019 19:10

JAK-inhibitors: an emerging treatment option for vitiligo

Presented By
Prof. John Harris, University of Massachusetts, USA
Conference
AAD 2019
Type
Peer-reviewed article

19 April 2019 13:53
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com